A carregar...
The Cannabinoid CB1 Antagonist TM38837 With Limited Penetrance to the Brain Shows Reduced Fear-Promoting Effects in Mice
Rimonabant was the first selective CB1 antagonist/inverse agonist introduced into clinical practice to treat obesity and metabolic-related disorders. It was withdrawn from market due to the notably increased rates of psychiatric side effects. We have evaluated TM38837, a novel, largely peripherally...
Na minha lista:
| Publicado no: | Front Pharmacol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6435594/ https://ncbi.nlm.nih.gov/pubmed/30949045 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2019.00207 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|